Literature DB >> 23830538

Changing referral characteristics of patients with autosomal dominant polycystic kidney disease.

Imed Helal1, Kim McFann, Berenice Reed, Xiang-Dong Yan, Robert W Schrier.   

Abstract

OBJECTIVE: Autosomal dominant polycystic kidney disease is the most frequent life-threatening hereditary disease. The study objective was to assess whether the clinical characteristics of patients with autosomal dominant polycystic kidney disease who are referred to a major autosomal dominant polycystic kidney disease center have changed over time.
METHODS: The clinical characteristics of patients with autosomal dominant polycystic kidney disease were compared between period A (1961-1990) and period B (1991-2011). The study took place at the Autosomal Dominant Polycystic Kidney Disease Center at the University of Colorado. A total of 837 patients referred with autosomal dominant polycystic kidney disease were included. Blood pressure control and renin-angiotensin-aldosterone system inhibition were instituted. Renal function, blood pressure, end-stage renal disease, and mortality were analyzed.
RESULTS: The results in period B compared with period A demonstrated an earlier age of autosomal dominant polycystic kidney disease diagnosis (29 vs 35 years, P < .001), lower mean blood pressure (129/82 vs 142/91 mm Hg, P < .001), better estimated glomerular filtration rate (63.6 vs 44.6 mL/min, P < .001), and more therapy with angiotensin-converting enzyme inhibition (42.5% vs 13.6%, P < .001). Time from birth to end-stage renal disease (52.8 ± 0.6 vs 49.1 ± 0.6 years, P < .001) and birth to death (63.5 ± 1.5 years vs 57.2 ± 1.0 years, P < .001) was longer in period B compared with period A when adjusted for age at diagnosis, sex, and estimated glomerular filtration rate. The study was retrospective, which is a limitation.
CONCLUSIONS: In period B, there was significantly better blood pressure control, more renin-angiotensin-aldosterone system inhibition, better preservation of renal function, and a longer period from birth to end-stage renal disease and death.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Angiotensin-converting enzyme inhibitor; Blood pressure; Chronic kidney disease; Renal progression

Mesh:

Year:  2013        PMID: 23830538     DOI: 10.1016/j.amjmed.2012.12.018

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  8 in total

1.  Decreasing incidence of renal replacement therapy over time at the critical 50-59-year age range suggests a role for nephroprotective therapy in ADPKD.

Authors:  Laura Rodriguez-Osorio; Maria Vanessa Perez-Gomez; Alberto Ortiz
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

2.  The Authors Reply.

Authors:  Edwin M Spithoven; Ron T Gansevoort
Journal:  Kidney Int       Date:  2015-07       Impact factor: 10.612

Review 3.  Current management of autosomal dominant polycystic kidney disease.

Authors:  Jacob A Akoh
Journal:  World J Nephrol       Date:  2015-09-06

4.  Overweight and Obesity Are Predictors of Progression in Early Autosomal Dominant Polycystic Kidney Disease.

Authors:  Kristen L Nowak; Zhiying You; Berenice Gitomer; Godela Brosnahan; Vicente E Torres; Arlene B Chapman; Ronald D Perrone; Theodore I Steinman; Kaleab Z Abebe; Frederic F Rahbari-Oskoui; Alan S L Yu; Peter C Harris; Kyongtae T Bae; Marie Hogan; Dana Miskulin; Michel Chonchol
Journal:  J Am Soc Nephrol       Date:  2017-11-08       Impact factor: 10.121

5.  Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease.

Authors:  Christopher M Blanchette; Caihua Liang; Deborah P Lubeck; Britt Newsome; Sandro Rossetti; Xiangmei Gu; Benjamin Gutierrez; Nancy D Lin
Journal:  Drugs Context       Date:  2015-04-17

6.  Incidence and survival of end-stage kidney disease due to polycystic kidney disease in Australia and New Zealand (1963-2014).

Authors:  Mangalee R Fernando; Hannah Dent; Stephen P McDonald; Gopala K Rangan
Journal:  Popul Health Metr       Date:  2017-02-17

7.  A Systematic Review of Reported Outcomes in ADPKD Studies.

Authors:  Sara S Jdiaa; Nedaa M Husainat; Razan Mansour; Mohamad A Kalot; Kerri McGreal; Fouad T Chebib; Ronald D Perrone; Alan Yu; Reem A Mustafa
Journal:  Kidney Int Rep       Date:  2022-07-05

8.  Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease.

Authors:  Katharina Hopp; Victoria A Catenacci; Nidhi Dwivedi; Timothy L Kline; Wei Wang; Zhiying You; Dustin T Nguyen; Kristen Bing; Bhavya Poudyal; Ginger C Johnson; Matthew R Jackman; Marsha Miller; Cortney N Steele; Natalie J Serkova; Paul S MacLean; Raphael A Nemenoff; Berenice Gitomer; Michel Chonchol; Kristen L Nowak
Journal:  iScience       Date:  2021-12-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.